Market
Sarepta Stands Behind Elevidys After FDA Requests Withdrawal Amid Safety Concerns
Sarepta; Elevidys; FDA; gene therapy; market withdrawal; safety concerns; Duchenne muscular dystrophy; deaths; clinical trial hold
FDA Threatens Action After Sarepta Refuses to Halt Elevidys Shipments
FDA; Sarepta Therapeutics; Elevidys; gene therapy; market withdrawal; patient deaths; Duchenne muscular dystrophy; liver failure; regulatory authority
Merck Wins FDA Approval for RSV Antibody Drug, Intensifying Market Competition
Merck; FDA approval; RSV; monoclonal antibody; infants; Enflonsia; competitive market; Sanofi; AstraZeneca
Odyssey Therapeutics Abandons IPO Plans in Latest Sign of Tough Environment for Biotech Listings
Odyssey Therapeutics; IPO; biotech; withdrawal; SEC; market turbulence; autoimmune
Struggling Biotechs Face Harsh Market as Funding and Clinical Successes Dry Up in 2025
biotech layoffs; market downturn; funding challenges; clinical trial failures; investor sentiment; M&A slowdown; job cuts; biotech sector
Sanofi Opens $130M ‘Flagship’ US Office Facility in Morristown, New Jersey
Sanofi; Morristown; flagship office; $130 million; healthcare; innovation; New Jersey; US market; corporate hub
Exit Strategy: Biopharma Professionals Consider Opportunities Outside Industry and US
biopharma talent; job market trends; industry transition; employment outside US; biopharma survey 2025; life sciences employment; biotech careers; pharmaceutical industry
Leqembi’s Expansion and Blood Test Impact: Analyst Sees Gradual Uptake Boost
Leqembi; Eisai; Biogen; Alzheimer’s disease; FDA approval; blood test; launch; maintenance dosing; autoinjector; subcutaneous; market adoption
Novo Nordisk CEO Departs Amid Weight-Loss Drug Market Pressures; Flagship Biotech Appoints CEO from Scholar Rock
Novo Nordisk; CEO departure; Lars Fruergaard Jørgensen; obesity drugs; weight-loss market; Eli Lilly competition; market challenges; Flagship Biotech; CEO appointment; Scholar Rock
Three-Month Drought in U.S. Biotech IPOs: Recent Developments and Context
biotech IPO; biotech market; IPO drought; 2025; biotech fundraising; biotech stocks